S100A2 and toxic epidermal necrolysis: To precisely evaluate the relationship between S100A2 expression and the severity of drug eruption, nine patients with severe-type drug eruption (Stevens–Johnson syndrome and toxic epidermal necrolysis) and 55 patients with mild-form drug eruption were enrolled in this study to clarify the degree of S100A2 expression in their skin (Table 2).